Crizotinib in ALK-positive lung cancer

被引：4
|
作者：
Girard, Nicolas [1 ]
机构：
[1] Louis Pradel Hosp, F-69500 Bron, France
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 10期
关键词：
ANAPLASTIC LYMPHOMA; CELL; KINASE;
D O I：
10.1016/S1470-2045(12)70375-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：962 / 963
页数：2
相关论文
共 50 条
  • [31] Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer
    Deng, Huiyan
    Li, Bin
    Li, Lina
    Peng, Jingcui
    Lv, Tongshuai
    Liu, Yueping
    Ding, Cuimin
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
  • [32] Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
    Gainor, Justin F.
    Sherman, Carol A.
    Willoughby, Kathryn
    Logan, Jennifer
    Kennedy, Elizabeth
    Brastianos, Priscilla K.
    Chi, Andrew S.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 232 - 236
  • [33] Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
    Biagio Ricciuti
    Andrea De Giglio
    Carmen Mecca
    Cataldo Arcuri
    Sabrina Marini
    Giulio Metro
    Sara Baglivo
    Angelo Sidoni
    Guido Bellezza
    Lucio Crinò
    Rita Chiari
    Medical Oncology, 2018, 35
  • [34] Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer
    Uemura, Takehiro
    Hida, Toyoaki
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (21)
  • [35] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (vol 368, pg 2385, 2013)
    不详
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (16): : 1582 - 1582
  • [36] Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
    Ricciuti, Biagio
    De Giglio, Andrea
    Mecca, Carmen
    Arcuri, Cataldo
    Marini, Sabrina
    Metro, Giulio
    Baglivo, Sara
    Sidoni, Angelo
    Bellezza, Guido
    Crino, Lucio
    Chiari, Rita
    MEDICAL ONCOLOGY, 2018, 35 (05)
  • [37] Optimal management of ALK-positive NSCLC progressing on crizotinib
    Metro, Giulio
    Tazza, Marco
    Matocci, Roberta
    Chiari, Rita
    Crino, Lucio
    LUNG CANCER, 2017, 106 : 58 - 66
  • [38] Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non-Small Cell Lung Cancer?
    Crystal, Adam S.
    Shaw, Alice T.
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4479 - 4481
  • [39] First-Line Crizotinib in ALK-Positive Lung Cancer (vol 372, pg 781, 2015)
    Tural, Deniz
    Saadettin, Kilickap
    Akan, Ali
    Koksoy, Elif B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (09): : 887 - 887
  • [40] Alectinib surpasses crizotinib for untreated ALK-positive NSCLC
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2017, 18 (07): : E377 - E377
12345